US FDA Snares Ozempic, Tremfya DTC Ads For Overstating Efficacy, GLP-1 Crackdown Continues

 
• By Sue Sutter
  
Violation notice
The FDA has issued nine untitled letters citing advertising and promotion violations in 2026. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from United States